Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement
Autoimmune Diseases
About this trial
This is an interventional treatment trial for Autoimmune Diseases focused on measuring Immunoglobulin G4-Related Disease, treatment strategies, relapse, leflunomide, mycophenolate mofetil
Eligibility Criteria
Inclusion Criteria: 1. Fulfillment of the 2019 American College of Rheumatology/European League against Rheumatology (ACR/EULAR) IgG4-related disease classification criteria; 2. Newly-onset or relapsed patients who requires initiation or continuation of glucocorticoids treatment; 3. The addition of glucocorticoids was started at lower than 10 mg/d. Exclusion Criteria: 1. Patients who were diagnosed as other autoimmune diseases; 2. Patients who were diagnosed as malignant diseases; 3. Pregnant and lactating women; 4. Active infection: HIV, HCV, HBV, TB; 5. Severe irreversible damage of organ function; 6. Receipt of any biologic therapy or immunosuppressive agent other than GCs.
Sites / Locations
- Peking Union Medical College HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Group I
Group II
Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 4 months. Afterwards, patients are treated with low dose mycophenolate (0.5-1g/day) during remission maintenance period for 9 months.
Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 4 months. Afterwards, patients are treated with leflunomide (10-20 mg/day) during remission maintenance period for 9 months.